Opinion: Combination immunotherapy may have failed in the Incyte/Merck trial, but it’s here to stay

Greater reliance on precision medicine and biomarkers will improve the testing of combination immunotherapy for cancer.

More From BioPortfolio on "Opinion: Combination immunotherapy may have failed in the Incyte/Merck trial, but it’s here to stay"